John Mendlein - Chairman, Fate Therapeutics


Dr. John Mendlein is executive chairman of four privately held biotech companies in San Diego: Fate Therapeutics, aTyr Pharm, Chimeros and Alevium. Prior to his involvement in these enterprises, he served as CEO of Adnexus Therapeutics from June 2005 until October 2007, at which time the privately-held, Boston based biotechnology company was purchased by Bristol-Myers Squibb Company in a transaction valued at more than $505 million. Previously, Mendlein served as chairman and CEO at Affinium Pharmaceuticals, Inc. and served in a variety of roles, including board member, general counsel and chief knowledge officer, at Aurora Biosciences (acquired by Vertex Pharmaceuticals). He is currently an advisory board member of Genesys Capital, a venture capital firm in Canada, a founder and board member of Homes for Sudan, a non-profit in Boston, and a scientific advisory board member for Ocean Discovery Institute, a non-profit in San Diego.

Chairman, Fate Therapeutics

Follow us

Twitter icon
Facebook icon
Google+ icon
LinkedIn icon
instagram icon

Copyright @ The World Technology Network. All Rights Reserved Back to Top

Back to Top